BR102020010923A2 - Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica ou hipocortisolismo - Google Patents
Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica ou hipocortisolismoInfo
- Publication number
- BR102020010923A2 BR102020010923A2 BR102020010923A BR102020010923A BR102020010923A2 BR 102020010923 A2 BR102020010923 A2 BR 102020010923A2 BR 102020010923 A BR102020010923 A BR 102020010923A BR 102020010923 A BR102020010923 A BR 102020010923A BR 102020010923 A2 BR102020010923 A2 BR 102020010923A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- implant
- polymer
- adrenal insufficiency
- release
- Prior art date
Links
- 239000007943 implant Substances 0.000 title abstract 8
- 208000017515 adrenocortical insufficiency Diseases 0.000 title abstract 7
- 206010001367 Adrenal insufficiency Diseases 0.000 title abstract 5
- 230000001684 chronic effect Effects 0.000 title abstract 5
- 229920000642 polymer Polymers 0.000 title abstract 5
- 230000002035 prolonged effect Effects 0.000 title abstract 5
- 239000013543 active substance Substances 0.000 title abstract 3
- 230000005923 long-lasting effect Effects 0.000 title abstract 3
- 238000007920 subcutaneous administration Methods 0.000 title abstract 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 229960000890 hydrocortisone Drugs 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica ou hipocortisolismo. o presente pedido de privilégio de invenção é voltado ao setor médico e compreende um implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica. o implante é inserido por via subcutânea e possui liberação contínua do ativo por um período de tempo prolongado. essa liberação visa garantir um nível sérico do fármaco eficiente, constante e prolongado para o tratamento da insuficiência adrenal crônica. o implante desse invento pode ter em sua constituição apenas a hidrocortisona, mas é preferencialmente formado por partículas de hidrocortisona dispersas homogeneamente em uma matriz polimérica bioerodível e bioabsorvível. essa matriz polimérica pode ser formada por um polímero ou uma mistura de polímeros. ainda, outra opção de implante para tratamento da insuficiência adrenal crônica são os implantes não biodegradáveis. a liberação da droga nesse sistema ocorre através da difusão, a uma taxa relativamente constante, e é possível alterar a velocidade de liberação da droga através da espessura ou material dessa membrana. nesse sistema há a necessidade de retirada do implante ao final do tratamento.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102020010923A BR102020010923A2 (pt) | 2020-05-29 | 2020-05-29 | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica ou hipocortisolismo |
PCT/BR2020/050345 WO2021237321A1 (pt) | 2020-05-29 | 2020-08-31 | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica ou hipocortisolismo |
US18/000,117 US20230190641A1 (en) | 2020-05-29 | 2020-08-31 | Long-lasting reabsorbable subcutaneous implant with sustained release of pre-concentrated pharmacologically active substance in polymer for the treatment of chronic adrenal insufficiency or hypocortisolism |
EP20938171.4A EP4159207A4 (en) | 2020-05-29 | 2020-08-31 | LONG-LASTING SUBCUTANEOUS IMPLANT WITH SUSTAINED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICAL ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF CHRONIC ADRENALINE INSUFFICIENCY OR HYPOCORTISOLISM |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102020010923A BR102020010923A2 (pt) | 2020-05-29 | 2020-05-29 | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica ou hipocortisolismo |
Publications (1)
Publication Number | Publication Date |
---|---|
BR102020010923A2 true BR102020010923A2 (pt) | 2021-12-14 |
Family
ID=78745713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR102020010923A BR102020010923A2 (pt) | 2020-05-29 | 2020-05-29 | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica ou hipocortisolismo |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230190641A1 (pt) |
EP (1) | EP4159207A4 (pt) |
BR (1) | BR102020010923A2 (pt) |
WO (1) | WO2021237321A1 (pt) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2054784T3 (es) | 1987-08-08 | 1994-08-16 | Akzo Nv | Un metodo para la fabricacion de un implante. |
US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
US20080317805A1 (en) * | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
WO2011139595A2 (en) * | 2010-04-27 | 2011-11-10 | Medtronic, Inc. | Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain |
US9173884B2 (en) * | 2011-11-30 | 2015-11-03 | Trustees Of Boston College | Inhibitors of phosphodiesterase 11 (PDE11) |
BR102016018206A2 (pt) * | 2016-08-08 | 2018-03-06 | Luiz Peracchi Edson | Pellet de hidrocortisona, reabsorvível aplicável na camada subcutânea, para tratamento de insuficiência adrenal crônica e doença de addison subclínica |
US10188602B2 (en) | 2016-09-29 | 2019-01-29 | Gesea Biosciences Inc. | Bioerodible implant for long-term drug delivery and associated methods of manufacture and use |
-
2020
- 2020-05-29 BR BR102020010923A patent/BR102020010923A2/pt not_active Application Discontinuation
- 2020-08-31 EP EP20938171.4A patent/EP4159207A4/en active Pending
- 2020-08-31 WO PCT/BR2020/050345 patent/WO2021237321A1/pt unknown
- 2020-08-31 US US18/000,117 patent/US20230190641A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4159207A1 (en) | 2023-04-05 |
EP4159207A4 (en) | 2024-04-17 |
US20230190641A1 (en) | 2023-06-22 |
WO2021237321A1 (pt) | 2021-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Caicco et al. | A hydrogel composite system for sustained epi-cortical delivery of Cyclosporin A to the brain for treatment of stroke | |
RU2008111827A (ru) | Система краткосрочной замедленной доставки лекарств для имплантируемых медицинских устройств и способ ее изготовления | |
Oh et al. | Prevention of postsurgical tissue adhesion by anti‐inflammatory drug‐loaded pluronic mixtures with sol–gel transition behavior | |
CN101854922A (zh) | 用于减轻、预防或治疗疼痛和炎症的具有不同释放曲线的长效制剂 | |
CN101835467B (zh) | 用于治疗疼痛和/或炎症的α-肾上腺素能受体激动剂 | |
Cesar et al. | Development and characterization of natural rubber latex and polylactic acid membranes for biomedical application | |
CN101969939B (zh) | 用于治疗炎性疾病的α-肾上腺素能受体激动剂 | |
CN111481513B (zh) | 缓释微球药物递送系统及其制备方法 | |
Choi et al. | Enhanced tendon restoration effects of anti-inflammatory, lactoferrin-immobilized, heparin-polymeric nanoparticles in an Achilles tendinitis rat model | |
US9504749B2 (en) | Medical devices and methods comprising an adhesive sheet containing a drug depot | |
US20110159072A1 (en) | Controlled release matrix | |
Tihan et al. | Collagen-based biomaterials for ibuprofen delivery | |
CA2720990A1 (en) | Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation | |
EP1827524A1 (en) | A method to enhance drug release from a composite material for implantation | |
Volokhova et al. | Controlled drug release from electrospun PCL non-woven scaffolds via multi-layering and e-beam treatment | |
US9205241B2 (en) | Medical devices and methods comprising an adhesive material | |
BR102020010923A2 (pt) | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da insuficiência adrenal crônica ou hipocortisolismo | |
CN101835465A (zh) | 生物可降解物质中的舒林酸制剂 | |
US9993441B2 (en) | Controlled release matrix barrier structure for subcutaneous medical devices | |
Valentino et al. | Design of novel mechanically resistant and biodegradable multichannel platforms for the treatment of peripheral nerve injuries | |
Algin-Yapar et al. | Evaluation of in vitro and in vivo performance of granisetron in situ forming implants: effect of sterilization, storage condition and degradation | |
CA2980916C (en) | Controlled release matrix barrier structure for subcutaneous medical devices | |
Modi | Effects of Neuregulin-1 on Peripheral Nerve Myelination | |
Nguyen et al. | Controlled release of vancomycin from PEGylated fibrinogen polyethylene glycol diacrylate hydrogel | |
Akbari et al. | Enhancing protein delivery for tissue regeneration: Development of AGR2-loaded hydrogels with controlled release properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11K | Dismissal acc. art. 17, par 2 of ipl - pending earlier application (priority claim) definitively shelved |
Free format text: PRIORIDADE INTERNA DO BR102021010270-5 DE 27/05/2021. |
|
B03F | Publication of an application: publication of application definitely dismissed [chapter 3.6 patent gazette] |